07:30 am

Registration and Morning coffee

08:15 am

Welcome and Introductory Remarks
CCS President - Andrew Judge, University of Florida, USA
Local Co-Host - Paola Costelli, University of Turin, Italy

Insights into cancer cachexia from the TRACERx lung study
Mariam Jamal-Hanjani, UCL Cancer Institute, UK

Integrative programs in patients with Lung Cancer
Silvia Novello, University of Turin, Italy

The transcriptomic landscape of human pancreatic cancer-associated cachexia
Jenny Permuth, Moffitt Cancer Center, USA

Serum miRNA signatures in cancer cachexia depends on systemic inflammation
Terese Louise Schmidberger Karlsen, NTNU, Norway

Cytokines involved in cachexia in mice and patients with non-small cell lung cancer
Cristina Munoz-Pinedo, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Spain 

Loss of skeletal muscle mass associates with poor survival and reduced cytotoxic T-cells in advanced lung cancer
Yan Sun, Maastricht university, Netherlands 

COFFEE BREAK

Spatiotemporal Metabolic Networks in Pancreatic Cancer and associated Cachexia
Nada Kalaany, Harvard Medical School, Boston Children's Hospital, USA

Changes in fibroblast composition promote pancreatic cancer-associated cachexia
Giulia Biffi, University of Cambridge, UK

Systemic influence of metastasis in cachexia
Salvador Aznar Benitah, ICREA Research Professor, IRB Barcelona, Spain

Tumour-borne ADAMTSL4 drives cancer cachexia via activation of the TGFbeta signalling pathway
Juliano Machado, Helmholtz Diabetes Center. Institute for Diabetes and Cancer, Germany

Muscle-tumor crosstalk in metastasis dissemination
Paolo Porporato, University of Turin, Italy

Pancreatic cancer cachexia is mediated by tumor-derived PTHrP
Jason Pitarresi, University of Massachusetts Chan Medical School, USA

LUNCH BREAK - Meet A Mentor

01:00 pm - 02:30 pm
Session C: Metabolic and Tissue Crosstalk in Cancer Cachexia
Chairs: Silvia Busquets, University of Barcelona, Spain;
            Laure Bindels, Université catholique de Louvain, Belgium

Identifying a new spatio-temporal coordinated response to cancer
Maria Rohm, Helmholtz Center Munich, Germany

Role of the liver-gut-muscle axis in the pathogenesis of cancer cachexia
Andrea Bonetto, University of Colorado Anschutz Medical Campus, USA

TBC
Lykke Sylow, University of Copenhagen, Denmark 

Genomic Profiling identifies hepatocyte-secreted factors that contribute to tissue wasting in cancer cachexia
Doris Kaltenecker, Insitute for Diabetes and Cancer, Helmholtz Munich, Germany 

A New Role for an Old Drug: Zoledronate as a Dual Agent Against Stemness and Cachexia in Ovarian Cancer
Fabrizio Pin, Indiana University School of Medicine, USA 

Machine Learning-Based Stratification of Cachexia Stages in a Murine Model Uncovers Multi-Tissue Transcriptomic Signatures
Robson Carvalho, Sao Paulo State University (UNESP), Brazil 

02:35 pm - 03:00 pm
Session D: Next Gen I
Chairs: Ross Dolan, University of Glasgow, UK;
           Daria Neyroud, University of Lausanne, Switzerland

IL-1beta Signaling Through MyD88 Drives Pro-Cachectic Suppressive Neutrophil Infiltration in Skeletal and Cardiac Muscle
Blake Roberts, University of Alberta, Canada 

Pancreatic Tumor Organoid Factors Induce Lipid Accumulation in Skeletal Muscle Cells from Individuals with Type 2 Diabetes and Alter Mitochondrial Function in Cachexia
Lara Stassen, Maastricht University, Netherlands

Targeting Metastasis to Combat Cancer-Associated Cachexia: Unraveling the Role of Host Metabolism in Metastasis and Cachexia Progression
Blanca Majem, Biomedical Research Institute of Barcelona, Spain 

Beyond Starvation: Exploring Hypermetabolism in Incurable Cancer
Marianne Erichsen, UiT The Arctic University of Norway, Norway

Bile acid dysregulation promotes cachexia in YAP-driven liver cancer
Madeline Webb, Peter Macallum Cancer Centre, Australia

COFFEE BREAK AND POSTER VIEWING

04:30 pm - 05:30 pm 
Session E: Kenneth CH Fearon Keynote Lectureship

Introduction: Fabio Penna, Italy
Keynote Speaker: Paola Costelli, Italy

05:30 - 07:00 pm
Welcome Reception - Aldo Moro

Registration and Morning Coffee

Early Promise, Early Access: Advancing Central Melanocortin Receptor Antagonists for Cancer Cachexia
Meghan Joly, PhD, Lead Clinical Scientist, Endevica Bio

09:00 am - 10:00 am
Session F: Central Regulation Systems of Feeding and Metabolism
Chairs: Mauricio Berriel Diaz, Helmholtz Center Munich, Germany;
           Vera Mazurak, University of Alberta, Canada

TBC
Tobias Janowitz, Cold Spring Harbor Laboratory, USA

Understanding the control of appetite in health and disease
Anthony Coll, University of Cambridge, UK

The GDF15-GFRAL axis elevates the metabolic rate and muscle lipid oxidation in cancer cachexia via the beta-adrenergic system
Steffen Raun, University of Copenhagen, Denmark

09:52 am

Race- and sex-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma
Margaret Park, Moffit Cancer Center, USA

COFFEE BREAK

10:30 am - 12:00 pm
Session G: Cancer-Induced Muscle Wasting and Associated Muscle Pathologies
Chairs: Roberta Sartori, University of Padova, Italy;
           Sarah Judge, University of Florida, USA

TBC
Stefan Anker, Charite, Germany

Whac-a-Mole or Occam’s Razor? Mechanisms of muscle loss in pancreatic cancer cachexia
Teresa Zimmers, Oregon Health & Science University, USA

TBC
Marco Sandri, Veneto Institute of Molecular Medicine, Dept Biomedical Sciences, University of Padova, Italy

Oxytocin counteracts muscle wasting and rescues muscle metabolism
Dario Coletti, Sapienza University of Rome, Italy 

Targeting a Novel Kinase to Mitigate Cancer Cachexia
Ajay Rana, University of Illinois at Chicago, USA 

Impaired cAMP/PKA/CREB1 signaling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia
Elia Angelino, Università del Piemonte Orientale, Italy

Pancreatic cancer alters gene expression in blood vessels within adipose tissue and muscle
Andreas Fischer, Göttingen University Medical Center, Germany

LUNCH BREAK - Meet A Mentor

Industry Symposium
Actimed Therapeutics

01:15 pm - 02:40 pm
Session H: Lifestyle Interventions for Cancer Cachexia
Chairs: Trude Rakel Balstad, Norwegian University of Science and Technology, Norway; 
           Calvin Cole, University of Rochester, USA

01:15 pm

Beyond Calories: Precision Nutrition in Cancer Cachexia
Paula Ravasco, Faculty of Medicine, Universidade Católica Portuguesa, Portugal

01:37 pm

TBC
Matthew Maddocks, King's College London, UK

01:59 pm

Exercise interventions to improve body composition in cancer survivors
Anouk Hiensch, University Medical Center Utrecht, Netherlands 

02:21 pm

Promising effects of muscle stimulation for function, muscle mass, and quality of life during stem cell transplant for hematologic malignancies
Lindsey Anderson, VA Puget Sound Health Care System, USA

02:29 pm

Can cachexia severity predict physical function phenotypes?
Ishan Roy, Shirley Ryan AbilityLab & Northwestern University, USA

02:37 pm

 Features of cachexia in patients with ovarian cancer and impact on performance in a structured oncologic exercise program
Leah Novinger, University of Colorado, USA

02:45 pm - 03:10 pm
Session I: Next Gen II
Chairs: Brittany Counts, Oregon Health & Science University, USA;
           Paige Arneson-Wissink, Oregon Health & Science University, USA

02:45 pm

Repurposing Dasatinib: A Novel Strategy to Attenuate Cancer-Associated Cachexia
Sai Vara Prasad Chitti, La Trobe University, Australia

02:50 pm

Does cachexia hinder the recognized benefits of physical activity in cancer patients?
Romane Peyrachon, Rennes 2 University M2S Lab, France

02:55 pm

From Pancreas to Periphery: Enzymatic Imbalance in Cancer Cachexia
Tuna Felix Samanci, Helmholtz Munich, Germany 

03:00 pm

Primary-stage colon cancer impairs muscle energy metabolism by suppressing mitochondrial complex I activity
Xiaolin Li, Wageningen University & Research, Netherlands

03:05 pm

Cancer-associated cachexia (CAC) rewires cholesterol metabolism to support tumorigenesis
Naama Darzi, Weizmann Institute of Science, Israel

03:10 pm

COFFEE BREAK AND POSTER VIEWING

04:40 pm - 06:00 pm
Session J:  Funding, Publishing & Regulatory Aspects of Cancer Cachexia
Chairs: TBC

04:40 pm

Cancer Grand Challenges: The Cachexia Grand Challenge.
Gemma Balmer-Kemp, Cancer Research, UK - Cancer Grand Challenges

05:05 pm

TBC
Naomi Lowy, Principal Drug Regulatory Expert, Hyman, Phelps & McNamara, P.C, USA – Regulatory Aspects of Cancer Cachexia Trials

05:30 pm

Meet the Editor Panel Discussion:
Ravati Dewal (Nature Metabolism)
Maria Garcia-Fernandez (Nature Communications)
Stefan Anker (J Cachexia Sarcopenia Muscle)

06:00 pm

Adjournment

06:45 - 09:30 pm
Social Reception - Palazzo del Rettorato

Registration and Morning coffee

           Erin Talbert, University of Iowa, USA

Smaller Patients, Bigger Challenges? Advances in Childhood Cancer Cachexia
Daniel Runco, Seattle Children's Hospital, USA - Pediatric Cancer Cachexia

TBC
Bette Caan, Kaiser Permanente Northern California, Division of Research, USA - Identification of Cachexia Subtypes

Contemplating contributing factors in cachexia
Paul Gregorevic, University of Melbourne, Australia - NMJ Preclinical

TBC
Richard Skipworth, Royal Infirmary of Edinburgh/University of Edinburgh, UK - NMJ Clinical

NMJ Q&A Discussion
Paul Gregorevic and Richard Skipworth

Pancreatic cancer promotes cardiac dysfunction through altered adrenergic signaling in the heart
Aaron Grossberg, Oregon Health & Science University, USA

Neuromuscular organoids mimic cancer induced muscle cachexia
Anna Urciuolo, University of Padova, Italy

COFFEE BREAK 

           Marcus Goncalves, NYU Grossman School of Medicine, USA

Cancer Patient Perspective on Cachexia

Caregiver Perspective on Cachexia

Cancer Cachexia Care: Perspectives from New York and Beyond
Marcus Goncalves, NYU Grossman School of Medicine, USA

TBC
Jose Garcia, University of Washington, USA

TBC
Matthew Maddocks, King's College London, UK

Beyond Calories: Precision Nutrition in Cancer Cachexia
Paula Ravasco, Faculty of Medicine, Universidade Católica Portuguesa, Portugal

TBC
Steven Olde Damink, Maastrict University, Netherland

Current Clinical Management of Cancer Cachexia
Eric Roeland, Oregon Health and Sciences University, Knight Cancer Institute, USA

Panel Discussion and Q&A (Audience & from Cancer Cachexia Network)

LUNCH BREAK

Clinical Development of Mifomelatide
Jillian L. Seiler, PhD, Senior Scientist, Endevica Bio

GDF-15 blockade - A multi-directional approach to potentiate cancer immunotherapy and alleviate cancer cachexia: The visugromab experience
Eugen Leo MD PhD MBA,Chief Medical Officer, CatalYm

Aveo

Pfizer

02:10 pm

Actimed

02:30 pm

TBC
Tateaki Naito, Shizuoka Cancer Center, Japan - Anamorelin

02:50 pm

COFFEE BREAK

Updating the ESPEN Guidelines on Nutrition in Patients with Cancer
Jan Arends, Universitätsklinik Freiburg, Germany 

Cachexia Care in Cancer Survivors
Tateaki Naito, Shizuoka Cancer Center, Japan 

           Xavier Clemente-Casares, University of Alberta, Canada

Acute cisplatin treatment alters neuromuscular homeostasis
Josh Huot, Indiana University School of Medicine, USA

The regulation of protein synthesis in cancer cachexia
Bert Blaauw, Veneto Institute of Molecular Medicine, Dept Biomedical Sciences, University of Padova, Italy

miR-379-3p counteracts cancer cachexia through regulation of mitochondrial stress and interferon response
Katarzyna Whysall, University of Galway,

Presentation of Awards and Closing Remarks

End of Conference